ImmunityBio (IBRX) Interest Coverage Ratio (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Interest Coverage Ratio of 0.91 for Q1 2026, up 78.08% year-over-year from 0.51 in Q1 2025, and up 79.22% quarter-over-quarter from 4.36 in Q4 2025.
ImmunityBio (IBRX) Interest Coverage Ratio (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Interest Coverage Ratio for 13 consecutive years, with 0.91 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 78.08% year-over-year to 0.91; the TTM figure through Mar 2026 stood at 3.39 (down 8.99% YoY), while the FY2025 annual figure was 0.3, up 32.46% from the prior year.
- Interest Coverage Ratio improved to 0.91 in Q1 2026 per IBRX's latest filing, from 4.36 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 4.55 in Q4 2022 and bottomed at 213.47 in Q4 2023.
- Historically, Interest Coverage Ratio has averaged 16.01 across 5 years, with a median of 3.65 in 2025.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio surged 125.78% — and 2023, when it tumbled 4790.11%.
- ImmunityBio's Interest Coverage Ratio stood at 4.55 in 2022, then sank by 4790.11% to 213.47 in 2023, then surged by 98.75% to 2.67 in 2024, then sank by 63.39% to 4.36 in 2025, then surged by 79.22% to 0.91 in 2026.
- Business Quant data shows IBRX's Interest Coverage Ratio at 0.91 in Q1 2026, 4.36 in Q4 2025, and 3.65 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | -0.61 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.61 |
| Mar 31, 2026 | -0.91 |
| Dec 31, 2025 | -4.36 |
| Sep 30, 2025 | -3.65 |
| Jun 30, 2025 | -4.61 |
| Mar 31, 2025 | -4.13 |
| Dec 31, 2024 | -2.67 |
| Sep 30, 2024 | -2.74 |
| Jun 30, 2024 | -3.33 |
| Mar 31, 2024 | -3.23 |
| Dec 31, 2023 | -213.47 |
| Sep 30, 2023 | -2.29 |
| Jun 30, 2023 | -2.64 |
| Mar 31, 2023 | -3.74 |
| Dec 31, 2022 | 4.55 |
| Sep 30, 2022 | -5.42 |
| Jun 30, 2022 | -8.21 |
| Mar 31, 2022 | -11.30 |
| Dec 31, 2021 | -17.66 |
| Sep 30, 2021 | -21.81 |